MML Investors Services
GALT icon

MML Investors Services’s Galectin Therapeutics GALT Stock Holding History

MML Investors Services’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-54,227
Closed -$90K – 2511
2023
Q4 		$90K Hold
54,227
– – ﹤0.01% 2392
2023
Q3 		$104K Hold
54,227
– – ﹤0.01% 2240
2023
Q2 		$78K Sell
54,227
-550
-1% -$933 ﹤0.01% 2260
2023
Q1 		$115K Hold
54,777
– – ﹤0.01% 1959
2022
Q4 		$62K Buy
54,777
+5,000
+10% +$6.66K ﹤0.01% 2115
2022
Q3 		$81K Buy
49,777
+11,000
+28% +$20.6K ﹤0.01% 2031
2022
Q2 		$51K Hold
38,777
– – ﹤0.01% 2004
2022
Q1 		$62K Buy
38,777
+5,000
+15% +$9.68K ﹤0.01% 2034
2021
Q4 		$70K Buy
33,777
+2,959
+10% +$8.45K ﹤0.01% 1991
2021
Q3 		$120K Hold
30,818
– – ﹤0.01% 1912
2021
Q2 		$99K Hold
30,818
– – ﹤0.01% 1871
2021
Q1 		$67K Hold
30,818
– – ﹤0.01% 1781
2020
Q4 		$69K Buy
30,818
+2,277
+8% +$5.97K ﹤0.01% 1651
2020
Q3 		$76K Hold
28,541
– – ﹤0.01% 1548
2020
Q2 		$87K Hold
28,541
– – ﹤0.01% 1488
2020
Q1 		$56K Buy
28,541
+6,400
+29% +$15.6K ﹤0.01% 1365
2019
Q4 		$63K Hold
22,141
– – ﹤0.01% 1487
2019
Q3 		$81K Sell
22,141
-6,652
-23% -$24K ﹤0.01% 1451
2019
Q2 		$119K Buy
28,793
+8,009
+39% +$34.7K ﹤0.01% 1558
2019
Q1 		$106K Sell
20,784
-6,142
-23% -$29.5K ﹤0.01% 1553
2018
Q4 		$92K Buy
26,926
+9,642
+56% +$46.1K ﹤0.01% 1461
2018
Q3 		$104K Sell
17,284
-3,227
-16% -$17.8K ﹤0.01% 1570
2018
Q2 		$130K Buy
20,511
+2,917
+17% +$14.2K ﹤0.01% 1316
2018
Q1 		$83K Sell
17,594
-9,619
-35% -$44.8K ﹤0.01% 1338
2017
Q4 		$91K Buy
27,213
+15,822
+139% +$40K ﹤0.01% 1364
2017
Q3 		$24K Buy
+11,391
New +$22.6K ﹤0.01% 1309

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MML Investors Services's GALT Position: Q1 2024 in Review

MML Investors Services sold out of Galectin Therapeutics (GALT) in Q1 2024, closing a stake of 54,227 shares — an estimated $90K sold.

MML Investors Services first reported a position in GALT in Q3 2017 and held it in 26 quarters. The position peaked at $130K in Q2 2018. 59 funds tracked by Wall St. Rank hold GALT as of Q1 2024.

  • MML Investors Services reported no remaining Galectin Therapeutics position as of Q1 2024 after selling out during the quarter.
  • MML Investors Services sold 54,227 Galectin Therapeutics shares in Q1 2024, an estimated $90K.
  • MML Investors Services first reported a position in Galectin Therapeutics in Q3 2017 and held it in 26 quarters.
  • MML Investors Services's Galectin Therapeutics position peaked at $130K in Q2 2018.
  • 59 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2024.

Based on MML Investors Services's 13F filing for Q1 2024, filed 14 May 2024.